Notice Regarding Submission of Business Improvement Plans

On April 13, 2010, Mitsubishi Tanabe Pharma Corporation and its subsidiary Bipha Corporation received an administrative action (suspension of business and order for improvement) issued by the Minister of Health, Labour and Welfare. This administrative action was issued in regard to a violation of the Pharmaceutical Affairs Act related to Medway Injection, a recombinant human serum albumin product. Mitsubishi Tanabe Pharma and Bipha have recently submitted their plans regarding business improvement measures and recurrence countermeasures to the Minister of Health, Labour and Welfare.

The main points of the business improvement plans are problem areas and causes of the incident, measures to correct those issues and recurrence countermeasures, and Groupwide initiatives to regain trust.

Everyone at the Mitsubishi Tanabe Pharma Group has reflected deeply on this incident, and Mitsubishi Tanabe Pharma and Bipha are giving the highest priority to the steady implementation of these business improvement plans. Moving forward, we will implement thorough countermeasures to prevent a recurrence of such an incident, and we will do our utmost to regain the trust of patients, medical professionals, and the rest of society.

〈For Details, Contact the Following Section〉
Corporate Communications Dept., Mitsubishi Tanabe Pharma Corporation
Tel +81-6-6205-5211